In honor of our fifth anniversary and our ongoing commitment to democratizing access to digital pathology worldwide, we will be offering the biggest promotion in our company’s history

Digital pathology is becoming an increasingly prevalent tool in laboratories and hospitals beyond the early pioneers in the West. The integration of Motic’s affordable and accessible digital pathology system has helped to bridge healthcare inequity gaps in underserved communities, significantly contributing to the advancement of cancer care, research, and discovery in Nigeria.

After years of experience in the digital pathology space, we’ve learned about many of the obstacles that customers have faced when adopting digital pathology. We often hear “It’s just too expensive”, “What specs really matter?”, or “I don’t even know where to start”. Here at Motic, we want to make the adoption process as easy as possible and answer the questions that you may have. This is why we’ve created this guide, which answers many of the FAQ’s and concerns that first-time adopters have had.

Vancouver, British Columbia – Motic, a leading provider of digital pathology solutions, today announced that the MoticEasyScan product line of Whole Slide Scanners obtained a Health Canada Class II Medical Device License. MoticEasyScan systems are now certified for Clinical use in Canada, introducing, for the first time, high-quality and affordable solutions to facilitate Digital Pathology adoption in Canada. Health Canada Class II certification will enable pathologists in Canada to use the MoticEasyScan scanners and software as diagnostic tools to scan, share and use whole-slide images for primary diagnosis.

The ability for digital pathology to help fight cancer in lower income countries is both one of the most recognized potentials of the technology, and also one of its least-often fulfilled. Motic’s goals for its new telepathology platform is to help affordably connect regional front-line hospitals with global medical professionals to advance healthcare and scientific discovery.

In this work, a team conducts an investigation of the expression of the CREB1 gene in ovarian cancer by deeply excavating the gene information in multiple databases and the mechanism.

Featured in April 2021’s edition of The Pathologist, various images scanned using a MoticEasyScan Pro were included in the “Picture Perfect Pathology,” editorial.